113 related articles for article (PubMed ID: 1717299)
1. The challenge of treating Graves'-Basedow's disease patients with antithyroid drugs (ATD) in a large university hospital.
Iacona A; Lima N; Perozim LM; Knobel M; Cavaliere H; Medeiros-Neto G
Exp Clin Endocrinol; 1991 May; 97(2-3):297-302. PubMed ID: 1717299
[No Abstract] [Full Text] [Related]
2. The evolution of the ophthalmopathy during antithyroid drug therapy and its relationship with serum thyroglobulin and antithyroglobulin antibody in patients with Basedow's disease.
Bromberg N; Werner RS; Sgarbi JA; Werner MC; Romaldini JH
Exp Clin Endocrinol; 1991 May; 97(2-3):354-7. PubMed ID: 1717300
[No Abstract] [Full Text] [Related]
3. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
[TBL] [Abstract][Full Text] [Related]
4. [Action of antithyroid drugs on the thyroid gland blood vessels in Basedow's disease].
Yamasaki T
Yonago Acta Med; 1966 Jul; 10(2):69-73. PubMed ID: 4167195
[No Abstract] [Full Text] [Related]
5. [Basedow's disease].
Scheidegger K
Schweiz Rundsch Med Prax; 1993 Aug; 82(32):840-4. PubMed ID: 7690495
[TBL] [Abstract][Full Text] [Related]
6. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
7. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
8. [The effect of thyrostatic treatment on circulating thyrotropin-receptor antibodies in Basedow's disease].
Lozanov B; Kirilov G; Ivanova R; Khubaveshki S
Vutr Boles; 1990; 29(3):79-84. PubMed ID: 1704667
[TBL] [Abstract][Full Text] [Related]
9. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
10. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
11. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
Eschmann SM; Thelen MH; Dittmann H; Bares R
Exp Clin Endocrinol Diabetes; 2006 May; 114(5):222-6. PubMed ID: 16804795
[TBL] [Abstract][Full Text] [Related]
12. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
[TBL] [Abstract][Full Text] [Related]
13. Concentration of TSH-receptor antibodies (TBII) in the sera of patients with immunogenic hyperthyroidism (Graves' disease) receiving antithyroid medication.
Budihna N; Pavlin K; Porenta M
Radiobiol Radiother (Berl); 1987; 28(1):101-6. PubMed ID: 2438715
[No Abstract] [Full Text] [Related]
14. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
Wu G; Jie Y; Situ Y
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
[TBL] [Abstract][Full Text] [Related]
15. [Combination of low doses of iodine 131 and synthetic antithyroid drugs in long-term care of Basedow's disease. Its value in the prevention of secondary hypothyroidism. (Apropos of 165 cases)].
Jaffiol C; Baldet L; Ghachem M; Robin M; Mirouze J
Sem Hop; 1973 Feb; 49(10):683-92. PubMed ID: 4122346
[No Abstract] [Full Text] [Related]
16. [Correlation between serum antithyroid antibody titer and changes in thyroid function during therapy of Graves' disease with antithyroid drugs].
Gao Y; Kong WL; Gao YM
Zhonghua Nei Ke Za Zhi; 1987 Feb; 26(2):86-9, 125. PubMed ID: 2440645
[No Abstract] [Full Text] [Related]
17. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease.
Bliddal H; Bech K; Kirkegaard C
Horm Metab Res; 1984 Nov; 16(11):602-5. PubMed ID: 6210237
[TBL] [Abstract][Full Text] [Related]
18. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
[TBL] [Abstract][Full Text] [Related]
19. [Effect of antithyroid treatment on the pituitary thyrotropin reserve in patients with Basedow's disease].
Gianrossi R; Murialdo G; Gallamini A; Rolandi E
Boll Soc Ital Biol Sper; 1976 Dec; 52(24):2082-7. PubMed ID: 71904
[No Abstract] [Full Text] [Related]
20. What can the European Multicenter Trial on the treatment of Graves' disease with antithyroid drugs teach us about the course of thyroid-associated orbitopathy (TAO)? European Multicenter Trial Group.
Benker G; Kahaly GJ; Reinwein D
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 5():S186-9. PubMed ID: 10614919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
